Rocket Pharmaceuticals (RCKT) Operating Expenses (2014 - 2026)

Rocket Pharmaceuticals (RCKT) has 13 years of Operating Expenses data on file, last reported at $48.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 24.66% year-over-year to $48.5 million; the trailing twelve-month figure through Mar 2026 stood at $215.9 million (down 20.11% YoY), and the FY2025 full-year result was $231.7 million, down 15.17% from the prior year.
• Operating Expenses climbed to $48.5 million in Q1 2026, from $44.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $73.7 million in Q2 2024 to a low of $42.6 million in Q1 2022.
• A 5-year average of $61.0 million and a median of $63.3 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses jumped 59.22% in 2022 and fell 29.88% in 2025, its largest moves.
• Tracing RCKT's Operating Expenses over 5 years: stood at $69.1 million in 2022, then dropped by 8.4% to $63.3 million in 2023, then declined by 0.92% to $62.7 million in 2024, then slipped by 29.88% to $44.0 million in 2025, then grew by 10.35% to $48.5 million in 2026.
• Business Quant data shows RCKT's Operating Expenses at $48.5 million in Q1 2026, $44.0 million in Q4 2025, and $52.2 million in Q3 2025.